Concepedia

Author

Jill Reckless

University of Cambridge

Also Known As

J P D Reckless, J Reckless, J. Reckless, J.P.D. Reckless, Jill RECKLESS, Jill Reckless, Reckless, J., Reckless, Jill

66

Publications

1K

Citations

16

H-Index

58

Concepts

All Affiliations

University of CambridgeAddenbrooke's HospitalMRC Laboratory of Molecular BiologyLawrence Berkeley National LaboratoryVHsquared (United Kingdom)
JR

About

Jill Reckless is an author at University of Cambridge specializing in medicine, immunology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

205

2

Natural Sciences

2

2

38

3

Biochemistry

2

2

38

4

Engineering

1

1

12

5

Biomedical Engineering

1

1

12

Jill Reckless

×

19

Publications

929

Citations

15

H-Index

YearCitations

Apolipoprotein E Modulates Clearance of Apoptotic Bodies In Vitro and In Vivo, Resulting in a Systemic Proinflammatory State in Apolipoprotein E-Deficient Mice

David J. Grainger, Jill Reckless, Elaine McKilligin

The Journal of Immunology

2004

179

Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice

Jill Reckless, James C. Metcalfe, David J. Grainger

Circulation

1997

91

Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms

Richard M. Salmon, Jingxu Guo, Jennifer Wood,

Nature Communications

2020

76

Neuroprotection in Ischemia–Reperfusion Injury: An Antiinflammatory Approach Using a Novel Broad-Spectrum Chemokine Inhibitor

John S. Beech, Jill Reckless, David E. Mosedale,

Journal of Cerebral Blood Flow & Metabolism

2001

72

Anaesthetic Impairment of Immune Function Is Mediated via GABAA Receptors

Daniel W. Wheeler, Andrew J. Thompson, Federico Corletto,

PLoS ONE

2011

71

Monocyte Chemoattractant Protein-1 but Not Tumor Necrosis Factor-α Is Correlated With Monocyte Infiltration in Mouse Lipid Lesions

Jill Reckless, Edward M. Rubin, Judy B. Verstuyft,

Circulation

1999

64

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

Jenny Crowe, Kevin J. Roberts, Timothy M. Carlton,

Scientific Reports

2018

56

Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice

Richard M. Lawn, Andrew D. Pearle, Lawrence L. Kunz,

Journal of Biological Chemistry

1996

55

The pan‐chemokine inhibitor NR58‐3.14.3 abolishes tumour necrosis factor‐α accumulation and leucocyte recruitment induced by lipopolysaccharide <i>in vivo</i>

Jill Reckless, Lauren M. Tatalick, David J. Grainger

Immunology

2001

48

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

Suhail Nurbhai, Kevin J. Roberts, Timothy M. Carlton,

Scientific Reports

2019

37

Page 1